Thus, depletion of SORLA increases the sensitivity of breast cancer cells to CADs, regardless of susceptibility to anti-HER2 therapy, presumably due to apoptosis triggered by lysosomal dysfunction. This evidence concerns the gene ERBB2 and breast cancer.